Eosinophilic Esophagitis Market Size & Share 2026-2035

Eosinophilic Esophagitis Market Size

The global eosinophilic esophagitis market was valued at USD 477.7 million in 2025. The market is expected to grow from USD 623.6 million in 2026 to USD 7.5 billion in 2035, at a CAGR of 31.8% during the forecast period, according to the latest report published by Global Market Insights Inc.

Eosinophilic esophagitis is a chronic immune system disease. With this disease, a type of white blood cell, called an eosinophil, builds up in the lining of the tube that connects the mouth to the stomach. This tube is also called the esophagus. This buildup, which is a reaction to foods, allergens, or acid reflux, can inflame or injure esophageal tissue.
 

Eosinophilic esophagitis is becoming increasingly recognized, particularly in western countries. The condition is more common in children and young adults but can affect individuals of any age. For instance, according to National Organization for Rare Diseases, the global prevalence for eosinophilic esophagitis is 142.5 cases out of 100,000. Thus, the global increase in the prevalence of eosinophilic esophagitis along with advancement in diagnostic technologies stimulates the growth of the market.
 

Furthermore, the market is stimulated by increasing awareness of eosinophilic esophagitis among both healthcare providers and the public that contribute to the increase in demand for new therapeutics options such as target specific drugs that promotes the growth of the market. Thus, the rising awareness among healthcare providers and patients and availability of advanced treatment landscape with new therapeutic options such as monoclonal antibodies and biologics, improves treatment outcomes for patients boosting the market growth.
 

Key players in the eosinophilic esophagitis market include Sanofi, Takeda Pharmaceutical, Ellodi Pharmaceuticals, EsoCap and AstraZeneca. These companies continue to drive innovation through the expansion of biologic treatment portfolios, late‑stage development of topical corticosteroid formulations, advancements in esophageal‑targeted delivery systems, and the acceleration of IL‑pathway therapeutic pipelines. Their combined efforts are instrumental in enhancing diagnostic precision, expanding targeted therapy options, and addressing the long‑term disease management needs of both adult and pediatric EoE populations worldwide.
 

Between 2022 and 2024, the eosinophilic esophagitis market experienced steady and sustained growth, driven by rising disease awareness, improved endoscopic and histopathological diagnostics, and increased adoption of targeted biologic therapies. During this period, the global market expanded from approximately USD 178.4 million in 2022 to USD 366.2 million in 2024. Growth was reinforced by a rising prevalence of EoE, increased investment in precision immunology‑based treatments, and broader access to modern esophageal disease management across both developed and emerging markets.
 

Eosinophilic Esophagitis Market Trends

• The development of new diagnostic tools and techniques, such as non-invasive biomarkers and improved endoscopic procedures, has significantly enhanced the detection and management of eosinophilic esophagitis that drive the growth of eosinophilic esophagitis industry.
   
• Also, the approval of new drugs by regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA) has a direct impact on the market by making new therapies available to patients and increasing treatment accessibility which is anticipated to boost market growth. For instance, Tezepelumab, a novel biologic that targets thymic stromal lymphopoietin (TSLP), is also being evaluated for its potential in treating eosinophilic esophagitis. While not yet approved for eosinophilic esophagitis, its ongoing trials demonstrate an increasing interest in biologic treatments. Thus, the ongoing clinical trials to launch new drug formulations are driving innovation in the market.
   
• As eosinophilic esophagitis becomes more widely recognized as a chronic immune‑mediated condition, coverage policies and reimbursement frameworks are expanding to support new diagnostics and advanced treatment options.
   
• The shift toward targeted immunologic therapies especially IL‑pathway biologics is accelerating as biologics demonstrate superior symptom control and histologic remission compared with traditional steroids.
   
• Moreover, improved molecular diagnostics and deeper understanding of immune‑pathway heterogeneity are paving the way for more individualized therapy selection in eosinophilic esophagitis management. High‑resolution endoscopy, enhanced histopathological techniques, and emerging biomarker tools are improving accuracy and reducing diagnostic delays.
   
• Also, global prevalence is climbing steadily, driven by improved awareness, higher diagnosis rates, and epidemiological growth across North America and Europe.
   
• A growing number of clinical studies globally reflect significant industry commitment to developing novel biologics, topical corticosteroids, and long‑acting delivery technologies. According to Global Data, there are 23 clinical trials for eosinophilic esophagitis.

Eosinophilic Esophagitis Market Analysis

Based on drug class, the market is divided into biologics, corticosteroids, proton pump inhibitors, immunomodulators, and other drug class. The corticosteroids segment dominated the market and was valued at USD 179 million in 2025.
 

• Corticosteroids, such as fluticasone propionate and budesonide, are widely used in the treatment of eosinophilic esophagitis due to their powerful anti-inflammatory properties.
   
• Moreover, corticosteroids offer rapid relief from the symptoms of eosinophilic esophagitis, such as dysphagia which means difficulty swallowing, chest pain, and food impact, making them first-line treatment in many cases. This contributes to their widespread use in the management of disease, especially when combined with dietary modifications and other therapies.
   
• Furthermore, the growing adoption of corticosteroid therapies in developing markets owing to increase in awareness and the management of disease boost market growth.
   
• Moreover, the biologics segment is the fastest growing segment, stimulated by increasing adoption of targeted immunotherapies, growing clinical preference for precision IL‑pathway inhibitors, and rising availability of advanced biologic options that significantly improve treatment outcomes in eosinophilic esophagitis.
   

Based on the route of administration, the global eosinophilic esophagitis market is categorized into injectable, oral, and topical. The oral segment dominated the market in 2025 and is anticipated to reach USD 3.2 billion by 2035.
 

• The oral route is non-invasive, making it easier for patients to self-administer drugs compared to injections or intravenous (IV) routes.
   
• Additionally, the development of novel oral biologics and small molecule API targeting specific pathways in eosinophilic esophagitis (such as IL-4, IL-5, or IL-13) has expanded the treatment options. Oral therapies, such as oral corticosteroids, are more effective in controlling symptoms, thereby contributing to the segmental growth.
   
• Moreover, oral medications are formulated to target the esophagus and can reduce the systemic side effects. Thus, oral therapies allow for safer long-term use compared to systemic treatments, which can result in significant side effects over time.
   

Based on age group, the global eosinophilic esophagitis market is categorized into pediatric, adults, and geriatric. The adults segment dominated the market in 2025 and is growing with a CAGR of 31.9% during the analysis period.
 

• The increased diagnosed cases for eosinophilic esophagitis in adults, contributing to market growth. Additionally, the prevalence of adult eosinophilic esophagitis is rising, due to better diagnostic methods, increased awareness, and a broader understanding of the disease's impact beyond childhood.
   
• Further, eosinophilic esophagitis is known to be historically underdiagnosed by adults, but growing awareness among physicians and patients has led to increased diagnoses that further support the growth of the market.
   
• Moreover, environmental factors, such as increased exposure to allergens and food triggers, are suspected to be contributing to the rise of eosinophilic esophagitis, particularly in adults.
   
• Furthermore, diet, environmental allergens, and genetic predispositions are some of the factors that are increasingly linked to eosinophilic esophagitis in adult population, leading to increasing demand for novel drug therapies, which boost market growth.
   
• Likewise, the pediatric segment is expanding steadily, driven by rising early‑age diagnosis, increasing awareness of childhood‑onset eosinophilic esophagitis, and growing access to targeted therapies.

Based on distribution channel, the eosinophilic esophagitis market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for the highest market share of 50.3% in 2025.
 

• The increasing awareness of eosinophilic esophagitis which require more patients seek diagnosis and treatment, which is typically initiated in hospital settings. Advanced diagnostic techniques such as endoscopy and biopsy are increasingly used in hospitals, prompting the need for specialized medications, contributing to segmental growth.
   
• Additionally, hospital pharmacies are often the first point of contact for patients receiving new and emerging treatments for eosinophilic esophagitis, such as biologic therapies such as Dupixent (dupilumab).
   
• Moreover, hospital pharmacies are expected to see growth due to the rising adoption of targeted therapies, such as corticosteroids and biologics. These therapies are often prescribed by specialists and require careful monitoring, which hospitals are equipped to manage.
   
• In contrast, the retail pharmacies segment continues to grow steadily, supported by increasing prescription fulfillment for corticosteroids and biologics, and improved patient accessibility to maintenance medications.

North America Eosinophilic Esophagitis Market 

The North America region dominated 45.5% share of the global eosinophilic esophagitis industry in 2025.
 

• North America leads the global market, supported by strong diagnostic capabilities, widespread specialist care, and rapid uptake of biologic therapies.
   
• The region benefits from high disease awareness and well‑established gastroenterology networks which drive early screening and consistent patient monitoring.
   
• Also, continuous introduction of novel therapies and strong access to specialty pharmacies sustain long‑term treatment growth.
   

The U.S. eosinophilic esophagitis market was valued at USD 73.8 million and USD 105.6 million in 2022 and 2023, respectively. The market size reached USD 197.3 million in 2025, growing from USD 151.3 billion in 2024.
 

• Eosinophilic esophagitis is known to be more commonly diagnosed in the U.S. due to increased awareness and better recognition. The prevalence is increasing, particularly among children and young adults, that further contributes to market growth. According to NIH, 39.5 cases in 100,000 cases of eosinophilic esophagitis are seen in U.S.
   
• Moreover, there has been a surge in funding for research into pathophysiology, diagnosis, and treatment of eosinophilic esophagitis. As a result, the U.S. is seeing more clinical trials and studies focusing on the disease, contributing to the development of new therapeutic approaches.
   

Europe Eosinophilic Esophagitis Market

Europe market accounted for USD 125.2 million in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• Europe maintains strong momentum due to rising eosinophilic esophagitis awareness, earlier referral pathways and expanded access to specialty gastroenterology care.
   
• Also, adoption of biologics and advanced topical therapies continues to grow as regulatory frameworks standardize across major countries such as Germany, UK, Italy and Spain.
   
• Strong clinical research participation supports rapid integration of innovative treatment approaches.
   

Germany shows strong growth potential in the Europe eosinophilic esophagitis market.
 

• The incidence of eosinophilic esophagitis in Germany, as well as in other parts of Europe, has been increasing. For instance, according to Deutsches Arzteblatt, the incidence of eosinophilic esophagitis is estimated to be 16.1 per 100,000 individuals, which stimulates the demand for eosinophilic esophagitis.
   
• Thus, the increase in prevalence coupled with change in lifestyle such as rise in westernized diets, environmental factors contributing to a higher number of individuals with allergic diseases, such as eosinophilic esophagitis is one of the primary factors driving the market growth.
   

Asia Pacific Eosinophilic Esophagitis Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 32.2% during the analysis timeframe.
 

• The expansion of gastroenterology centers and improved endoscopic capabilities are driving increased eosinophilic esophagitis detection across the region.
   
• Also, growing healthcare investment and adoption of international treatment guidelines support market growth.
   
• Rising prevalence of allergic disorders aligns with increased recognition of eosinophilic esophagitis as an emerging clinical concern.
   

China eosinophilic esophagitis market is estimated to grow with a significant CAGR, in the Asia Pacific market.
 

• The healthcare system in China has been undergoing significant reform and improvement in recent years, providing better access to diagnostic tools such as endoscopy and biopsy procedures to diagnose eosinophilic esophagitis.
   
• The increasing elderly population in China and rapid increase in urbanization leads to a greater number of people adopting sedentary lifestyles, which can exacerbate conditions like obesity and gastrointestinal diseases, leading to an increase in eosinophilic esophagitis, which propel the market growth.
   

Latin American Eosinophilic Esophagitis Market

Brazil leads the Latin American eosinophilic esophagitis industry, exhibiting remarkable growth during the analysis period.
 

• Brazil’s rapidly changing dietary patterns, with increased consumption of processed foods and allergens, are contributing to a rise in eosinophilic esophagitis cases. Environmental factors, such as exposure to allergens, may also be increasing.
   
• Furthermore, the Brazilian government has been focusing on improving chronic disease management, including conditions such as eosinophilic esophagitis.
   
• Additionally, initiatives aimed at better diagnostic infrastructure and funding for chronic illness management are expected to boost the market.
   

Middle East and Africa Eosinophilic Esophagitis Market

Saudi Arabia eosinophilic esophagitis industry is expected to experience substantial growth in the Middle East and Africa market in 2025.
 

• Saudi Arabia has observed a rise in allergic conditions, including food allergies, which are linked to eosinophilic esophagitis. The increasing prevalence of these allergies contributes to a higher incidence of eosinophilic esophagitis cases, thereby expanding the patient population requiring treatment.
   
• Moreover, Saudi Arabia has been investing in its healthcare infrastructure, leading to improved diagnostic capabilities and better patient care. Enhanced awareness among healthcare providers and the public about eosinophilic esophagitis contributes to earlier diagnosis and treatment, positively impacting the market.
   

Eosinophilic Esophagitis Market Share

The global eosinophilic esophagitis industry is characterized by a highly consolidated yet competitive landscape, with a small group of leading companies accounting for a substantial share of global revenues. Sanofi, Takeda Pharmaceutical, Ellodi Pharmaceuticals, EsoCap and AstraZeneca collectively hold approximately 65% of the global market, supported by their leadership in biologic therapies, esophagus‑targeted drug delivery technologies, and innovation‑driven development pipelines. These companies dominate key therapeutic categories within the eosinophilic esophagitis space, leveraging strengths in biologics, topical corticosteroids, precision delivery platforms, and advanced immunology‑based treatment modalities.
 

Strategic expansion through clinical collaborations, regulatory advancement and technologically enabled formulation innovation continues to define the competitive environment. Sanofi has strengthened its leadership through broad adoption of Dupixent, while Takeda has expanded its footprint with the launch of Eohilia and investments in specialized esophageal drug technologies. Ellodi Pharmaceuticals, EsoCap and AstraZeneca are actively evolving their pipelines with next‑generation therapies including targeted biologics, optimized corticosteroid formats, and advanced esophageal delivery solutions reflecting rising focus on personalized immunologic treatment strategies.
 

Leading companies are intensifying efforts to accelerate development of biologics, esophageal‑targeted formulations, novel immunomodulators and integrated diagnostic‑therapeutic pathways. This momentum is stimulated by increasing disease prevalence, broader clinical recognition, and strong demand for long‑term, mechanism‑based management of eosinophilic esophagitis. As precision medicine, non‑invasive diagnostics, and IL‑pathway inhibitors advance, top competitors are well‑positioned to capture sustained market growth through innovative therapies, deep R&D investment, and expanding specialty‑care distribution networks.
 

Eosinophilic Esophagitis Market Companies

Prominent players operating in the eosinophilic esophagitis industry are as mentioned below:

• Allakos
• Arena Pharmaceuticals
• AstraZeneca
• Cipla
• Ellodi Pharmaceuticals
• EsoCap
• GlaxoSmithKline
• Revolo Biotherapeutics
• Sanofi
• Sun Pharmaceutical
• Takeda Pharmaceutical
• Teva Pharmaceutical 
   
• Sanofi

Sanofi holds the leading position in the global EoE therapeutics market, driven by the strong commercial success of Dupixent, the first widely adopted biologic for eosinophilic esophagitis. The company’s leadership is reinforced by its robust immunology expertise, extensive global footprint, and continued investment in expanding biologic indications, ensuring broad patient access and sustained market dominance.
 

• Takeda Pharmaceutical

Takeda maintains a powerful competitive standing in the EoE market through Eohilia, the first and only FDA‑approved oral therapy specifically developed for eosinophilic esophagitis. The company continues to strengthen its position through advanced esophageal‑targeted drug delivery technologies, strategic regulatory achievements, and ongoing expansion of its specialty care portfolio.
 

• Ellodi Pharmaceuticals

Ellodi Pharmaceuticals plays a significant role in the EoE treatment landscape through its focus on developing esophagus‑targeted therapeutic solutions designed to deliver localized anti‑inflammatory benefits. Its specialized approach, innovation‑driven drug design, and dedication to addressing unmet needs within eosinophilic esophagitis reinforce Ellodi’s emerging influence in this rapidly evolving market.
 

Eosinophilic Esophagitis Industry News

• In February 2024, Takeda announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), for people 11 years and older with eosinophilic esophagitis. This helped the company expand its product range.
   
• In January 2024, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis. This approval aimed to broaden the treatment availability, complementing existing therapies for eosinophilic esophagitis.
   

The eosinophilic esophagitis market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Biologics
• Corticosteroids
• Proton pump inhibitors
• Immunomodulators
• Other drug class

Market, By Route of Administration

• Oral
• Injectable
• Topical

Market, By Age Group

• Pediatric
• Adults
• Geriatric

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE